Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 5 records in total 5
    records per page

    Multiple Myeloma MESHD Multiple Myeloma HP and SARS-CoV-2 Infection MESHD: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

    Authors: Joaquin Martinez-Lopez; Maria-Victoria Mateos; Cristina Encinas; Anna Sureda; Jose Angel Hernandez-Rivas; Ana Lopez de la Guia; Diego Conde; Isabel Krsnik; Elena Prieto; Rosalia Riaza Grau; Mercedes Gironella; Maria Jesus Blanchard; Nerea Caminos; Carlos Fernandez de Larrea; Maria Alicia Senin; Fernando Escalante; Jose Enrique de la Puerta; Eugenio Gimenez; Pilar Martinez-Barranco; Juan Jose Mateos; Luis Felipe Casado; Joan Blade; Juan Jose Lahuerta; Javier De La Cruz; Jesus San-Miguel

    doi:10.1101/2020.06.29.20142455 Date: 2020-06-30 Source: medRxiv

    There is limited information on the characteristics, pre-admission prognostic factors, and outcomes of patients with multiple myeloma MESHD multiple myeloma HP (MM) hospitalized with coronavirus disease MESHD 2019 (COVID-19). This retrospective case series investigated characteristics and outcomes of 167 MM patients hospitalized with COVID-19 reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in Spain between March 1 and April 30, 2020. Outcomes were compared with a randomly selected contemporary cohort of 167 age TRANS-/sex-matched non-cancer patients with COVID-19 admitted at 6 participating hospitals. Common demographic, clinical, laboratory, treatment, and outcome variables were collected; specific disease MESHD status and treatment data were collected for MM patients. Among the MM and non-cancer patients, median age TRANS was 71 years and 57% of patients were male TRANS in each series, and 75% and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77% and 89% of patients and critical in 8% and 4%, respectively. Supplemental oxygen was required by 47% and 55% of MM and non-cancer patients, respectively, and 21%/9% vs 8%/6% required non-invasive/invasive ventilation. Inpatient mortality was 34% and 23% in MM and non-cancer patients, respectively. Among MM patients, inpatient mortality was 41% in males TRANS, 42% in patients aged TRANS >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease MESHD at hospitalization, which were independent prognostic factors of inpatient mortality on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.

    COVID-19 infections MESHD and outcomes in patients with multiple myeloma MESHD multiple myeloma HP in New York City: a cohort study from five academic centers

    Authors: Malin Hultcrantz; Joshua Richter; Cara Rosenbaum; Dhwani Patel; Eric Smith; Neha Korde; Sydney Lu; Sham Mailankody; Urvi Shah; Alexander Lesokhin; Hani Hassoun; Carlyn Tan; Francesco Maura; Andriy Derkach; Benjamin Diamond; Adriana Rossi; Roger N Pearse; Deppu Madduri; Ajai Chari; David Kaminetzky; Marc Braunstein; Christian Gordillo; Faith Davies; Sundar Jagannath; Ruben Niesvizky; Suzanne Lentzsch; Gareth Morgan; Ola Landgren

    doi:10.1101/2020.06.09.20126516 Date: 2020-06-11 Source: medRxiv

    Importance: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma MESHD multiple myeloma HP have a compromised immune system, due to both the disease MESHD and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease MESHD 2019 (COVID-19); however, there is limited information to guide clinical management. Objective: To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma MESHD multiple myeloma HP. Design: Case-series. Setting: Five large academic centers in New York City. Participants: Patients with multiple myeloma MESHD multiple myeloma HP and related plasma SERO cell disorders who were diagnosed with COVID-19 between March 10th, 2020 and April 30th, 2020. Exposures: Clinical features and risk factors were analyzed in relation to severity of COVID-19. Main Outcomes and Measures: Descriptive statistics as well as logistic regression were used to estimate disease MESHD severity reflected in hospital admissions, intensive care unit (ICU) admission, need for mechanical ventilation, or death MESHD. Results: Of 100 multiple myeloma MESHD multiple myeloma HP patients ( male TRANS 58%; median age TRANS 68, range 41-91) diagnosed with COVID-19, 74 (74%) were admitted; of these 13 (18%) patients were placed on mechanical ventilation, and 18 patients (24%) expired. None of the studied risk factors were significantly associated (P>0.05) with adverse outcomes (ICU-admission, mechanical ventilation, or death MESHD): hypertension MESHD hypertension HP (N=56) odds ratio (OR) 2.3 (95% confidence interval [CI] 0.9-5.9); diabetes (N=18) OR 1.1 (95% CI 0.3-3.2); age TRANS >65 years (N=63) OR 2.0 (95% CI 0.8-5.3); high dose melphalan with autologous stem cell transplant <12 months (N=7) OR 1.2 (95% CI 0.2-7.4), IgG<650 mg/dL (N=42) OR=1.2 (95% CI 0.4-3.1). In the entire series of 127 patients with plasma SERO cell disorders, hypertension MESHD hypertension HP was significantly associated with the combined end-point (OR 3.4, 95% CI 1.5-8.1). Conclusions and Relevance: Although multiple myeloma MESHD multiple myeloma HP patients have a compromised immune system due to both the disease MESHD and therapy; in this largest disease MESHD specific cohort to date of patients with multiple myeloma MESHD multiple myeloma HP and COVID-19, compared to the general population, we found risk factors for adverse outcome to be shared and mortality rates to be within the higher range of officially reported mortality rates.

    A tertiary center experience of multiple myeloma MESHD multiple myeloma HP patients with COVID-19: lessons learned and the path forward

    Authors: Bo Wang; Oliver Van Oekelen; Tarek Mouhieddine; Diane Marie Del Valle; Joshua Richter; Hearn Jay Cho; Shambavi Richard; Ajai Chari; Sacha Gnjatic; Miriam Merad; Sundar Jagannath; Samir Parekh; Deepu Madduri

    doi:10.1101/2020.06.04.20122846 Date: 2020-06-05 Source: medRxiv

    Background: The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths MESHD in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma MESHD multiple myeloma HP (MM) population. Herein, we report the characteristics of COVID-19 infection MESHD and serological response in MM patients in a large tertiary care institution in New York. Methods: We performed a retrospective study on a cohort of 58 patients with a plasma SERO-cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti- SARS-CoV-2 antibody SERO testing, treatments initiated, and outcomes. Results: Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age TRANS was 67 years; 52% of patients were male TRANS and 63% were non-white. Hypertension MESHD Hypertension HP (64%), hyperlipidemia MESHD hyperlipidemia HP (62%), obesity MESHD obesity HP (37%), diabetes mellitus MESHD diabetes mellitus HP (28%), chronic kidney disease HP kidney disease MESHD (24%) and lung disease MESHD (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age TRANS (>70 years), male TRANS sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p<0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p<0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-white race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 SERO at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR. Conclusions: Drug exposure and MM disease MESHD status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia were associated with higher mortality. The majority of patients mounted an antibody SERO response to SARS-CoV-2. These findings pave a path to identification of vulnerable MM patients who need early intervention to improve outcome in future outbreaks of COVID-19.

    Evaluation of COVID 19 infection MESHD in 279 cancer patients treated during a 90-day period in 2020 pandemic

    Authors: Mozaffar Aznab

    doi:10.1101/2020.05.26.20102889 Date: 2020-06-01 Source: medRxiv

    Background: The aim of this study was investigation of COVID-19 disease MESHD and its outcome in cancer patients who needed treatment, in a 90-day period. Methods: Cancer patient who required treatment, were evaluated for potential COVID-19 infection MESHD in a 90-day period, starting from beginning of this epidemic in Iran, January, to April 19, 2020. For treatment of solid tumor patients, if they did not have symptoms related to COVID-19, just chest X-ray was requested. If they showed COVID-19 related symptoms, High Resolution CT scan of lungs was requested. For hematology cancer patients, PCR test for COVID-19 infection MESHD was requested as well. Protection measures were considered for personnel of oncology wards. Results: In this study, 279 patients were followed up in this 90-day period. No COVID-19 infection MESHD was observed in 92 cases of breast cancer, 72 cases of colon cancer HP, 14 cases of gastric cancer and 12 cases of pancreaticobiliary cancer .However, in 11 cases of lung cancer, 5 cases brain tumors and 12 cases ovarian cancer; 3 case of COVID-19 were observed. In the hematology cancers group, which included 14 cases of Hodgkin Lymphoma HP Lymphoma MESHD, 23 cases of lymphoproliferative disorder MESHD lymphoproliferative disorder HP, 12 cases of acute leukemia HP leukemia MESHD and 12 cases of multiple myeloma MESHD multiple myeloma HP; three of COVID-19 were observed. Conclusion: Patients with cancer who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients awareness particularly about self-care behavior, performing a COVID-19 test, and taking a chest X ray, before the treatment starts

    Thalidomide-Revisited: Are COVID-19 Patients Going to be the Latest Victims of Yet Another Theoretical Drug-Repurposing?

    Authors: Athar khalil; Amina Kamar; Georges Nemer

    id:10.20944/preprints202005.0029.v1 Date: 2020-05-03 Source:

    The new pandemic coronavirus disease MESHD 2019 (COVID-19) is a worldwide threatening health issue. Early progression of this disease MESHD starts in the lung airways with an exaggerated inflammation MESHD, triggered by the viral infection MESHD and characterized by a “cytokine storm” that can lead to lethal lung injuries MESHD. In the absence of an effective anti-viral molecule and until the formulation of a successful vaccine, anti-inflammatory drugs might offer a complementary tool for controlling the associated complications and thus decreasing the subsequent fatalities. Drug repurposing for several molecules has emerged as a rapid temporary solution for COVID-19. Among these drugs, Thalidomide, a historically emblematic controversial molecule that harbors an FDA approval for treating Erythema Nodosum MESHD Erythema Nodosum HP Leprosum (ENL) and multiple myeloma MESHD multiple myeloma HP (MM). Based on only one-case report of positive outcomes in a patient treated amongst others with Thalidomide, two clinical trials on the efficacy and safety of Thalidomide in treating severe respiratory complications in COVID-19 patients were registered. Conversely, the absence of any substantial, promising evidence on Thalidomide usage in that context along with the discontinued studies on the efficiency of this drug in similar pulmonary diseases MESHD might cause a significant obstacle for carrying on clinical studies. In this review, we will discuss the theoretical effectiveness of this drug in attenuating inflammatory complications that are encountered in patients with COVID-19 while pinpointing the lack of evidence that is needed to move forward with this drug.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.